Lantheus Holdings, Inc. and TG Therapeutics, Inc.: A Comprehensive Revenue Analysis

Biotech Giants' Revenue Surge: A Decade of Growth and Innovation

__timestamp	Lantheus Holdings, Inc.	TG Therapeutics, Inc.
Wednesday, January 1, 2014	301600000	152381
Thursday, January 1, 2015	293461000	152381
Friday, January 1, 2016	301853000	152381
Sunday, January 1, 2017	331378000	152381
Monday, January 1, 2018	343374000	152000
Tuesday, January 1, 2019	347337000	152000
Wednesday, January 1, 2020	339410000	152000
Friday, January 1, 2021	425208000	6689000
Saturday, January 1, 2022	935061000	2785000
Sunday, January 1, 2023	1296429000	233662000

Data in motion

A Tale of Two Biotech Giants: Lantheus Holdings and TG Therapeutics

In the ever-evolving landscape of biotechnology, Lantheus Holdings, Inc. and TG Therapeutics, Inc. have carved distinct paths over the past decade. From 2014 to 2023, Lantheus Holdings has demonstrated a remarkable growth trajectory, with revenue surging by over 330%, reaching a peak in 2023. This growth underscores their strategic advancements in medical imaging and diagnostics.

Conversely, TG Therapeutics, Inc. has experienced a more volatile journey. Despite a modest start, their revenue saw a dramatic increase in 2023, marking a pivotal year with a staggering 9,000% rise compared to 2021. This leap highlights their breakthrough in therapeutic solutions.

The contrasting revenue trends of these companies reflect their unique market strategies and innovations, offering valuable insights into the dynamic biotech sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025